Percutaneous Cardiovascular Procedures DRG 321 Reimbursement

Summary & Overview

Percutaneous Cardiovascular Procedures with Intraluminal Device with MCC or 4+ Arteries/Intraluminal Devices: Inpatient Reimbursement Overview

DRG 321 encompasses complex percutaneous cardiovascular procedures with intraluminal device placement involving a Major Complication or Comorbidity or procedures on four or more arteries or devices. It matters for inpatient reimbursement because it identifies high-resource cardiovascular interventions that lead to elevated Medicare payment relative to less complex procedural groups.

Percutaneous Cardiovascular Procedures with Intraluminal Device with MCC or 4+ Arteries/Intraluminal DevicesDRG Percutaneous Cardiovascular Procedures with Intraluminal Device with MCC or 4+ Arteries/Intraluminal DevicesDRG 321Diagnosis-Related GroupInpatient ReimbursementMedicareCardiologyPercutaneous Coronary InterventionEndovascular Procedures

DRG 321 Overview

DRG 321 covers percutaneous cardiovascular procedures involving placement of intraluminal devices with a Major Complication or Comorbidity or interventions involving four or more arteries or intraluminal devices. Typical cases include complex percutaneous coronary interventions with multiple stents or other endovascular devices accompanied by significant comorbidity. This Diagnosis-Related Group is important for Medicare payment because it captures higher-resource, higher-risk inpatient encounters that affect reimbursement levels. Understanding the clinical scope helps clarify payment categorization and hospital case-mix implications.

National Payment Rates

Across payers the observed rate range spans from about $21K (BCBS mean) up to $44K (Cigna mean), with individual payer means between $31K and $44K; the widest spread between payer means is approximately $23K. See the table and chart below for percentile detail and distributional context. Full payer labels are shown alongside the numeric benchmarks in the table.

Mean Rates by Payer — National — DRG 321

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported in the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment, and total discharges for DRG 321. These values summarize Medicare payment experience nationally for the DRG in 2023.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Payer means for DRG 321 in Alaska range from $40K (Anthem and Blue Cross Blue Shield) up to $68K (Cigna), reflecting a wide local rate dispersion across payers. Cigna’s mean at $68K is the most notable deviation, sitting well above the other in-state payers and above many national averages. Reference the table and chart below for payer-level distributions and percentile detail.

Key Insights for Alaska

Highest-paying payer: Cigna (mean $68K); Lowest-paying payer(s): Anthem and Blue Cross Blue Shield (mean $40K).
Alaska’s payer means span a wide range ($40K to $68K), with Cigna substantially above the other local payers and notably higher than national mean benchmarks for several payers.

Clinical Trials

Acute procedural optimization studies assessing percutaneous coronary interventions (PCI) with multiple stents or intraluminal devices in high-risk anatomies: randomized or pragmatic trials focus on intra-procedural strategies (e.g., imaging-guided deployment, adjunctive atherectomy, staged vs. single-session multivessel PCI) among patients presenting with complex coronary disease requiring treatment of four or more arteries or multiple devices. These studies enroll inpatients undergoing index percutaneous cardiovascular procedures and evaluate immediate procedural success, complication rates (bleeding, vessel dissection, distal embolization), and length of stay. Findings inform interventional technique standards and resource utilization that directly affect inpatient costs and DRG-level reimbursement considerations for complex PCI cases.
Comparative effectiveness research comparing device types and antithrombotic strategies in patients treated with multiple intraluminal devices: observational cohorts or randomized comparative trials examine outcomes for different stent platforms, bioresorbable scaffolds, or adjunctive device use and concurrent antiplatelet/anticoagulant regimens in medically complex patients with multivessel disease. These studies target typical DRG 321 patients who have higher comorbidity burdens (e.g., diabetes, CKD, prior CABG) to assess revascularization durability, repeat revascularization rates, and inpatient adverse events. Results help clinicians and payers evaluate value (clinical benefit vs. cost and complication risk) of specific device and pharmacologic choices in the inpatient setting where device costs and complication-driven expenditures are concentrated.
Post-discharge outcomes and care-transition studies focused on readmission, rehabilitation, and long-term health resource use after complex percutaneous interventions: cohort studies and pragmatic trials evaluate discharge planning, cardiac rehabilitation referral, medication adherence interventions, and early outpatient follow-up timing for patients who underwent PCI with multiple intraluminal devices. The population includes survivors of complex index procedures whose post-acute care needs and readmission risk are elevated due to extensive revascularization and comorbid conditions; endpoints include 30- and 90-day readmissions, major adverse cardiovascular events, and cumulative post-discharge costs. This area is relevant to providers and payers because reducing readmissions and optimizing post-discharge management can substantially impact total cost of care and quality metrics tied to DRG payments.

Related Codes

231-CORONARY-BYPASS-WITH-PTCA-WITH-MCC

Coronary Bypass with PTCA with MCC: Inpatient Reimbursement Overview

271-OTHER-MAJOR-CARDIOVASCULAR-PROCEDURES-WITH-CC

Other Major Cardiovascular Procedures with CC: Inpatient Reimbursement Overview

299-PERIPHERAL-VASCULAR-DISORDERS-WITH-MCC

Peripheral Vascular Disorders with MCC: Inpatient Reimbursement Overview

305-HYPERTENSION-WITHOUT-MCC

Hypertension without MCC: Inpatient Reimbursement Overview

266-ENDOVASCULAR-CARDIAC-VALVE-REPLACEMENT-AND-SUPPLEMENT-PROCEDURES-WITH-MCC

Endovascular Cardiac Valve Replacement and Supplement Procedures with MCC: Inpatient Reimbursement Overview

273-PERCUTANEOUS-AND-OTHER-INTRACARDIAC-PROCEDURES-WITH-MCC

Percutaneous and Other Intracardiac Procedures with MCC: Inpatient Reimbursement Overview

307-CARDIAC-CONGENITAL-AND-VALVULAR-DISORDERS-WITHOUT-MCC

Cardiac Congenital and Valvular Disorders without MCC: Inpatient Reimbursement Overview

234-CORONARY-BYPASS-WITH-CARDIAC-CATHETERIZATION-OR-OPEN-ABLATION-WITHOUT-MCC

Coronary Bypass with Cardiac Catheterization or Open Ablation without MCC: Inpatient Reimbursement Overview

302-ATHEROSCLEROSIS-WITH-MCC

Atherosclerosis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

264-OTHER-CIRCULATORY-SYSTEM-O-R-PROCEDURES

Other Circulatory System O.R. Procedures: Inpatient Reimbursement Overview

Showing 1–10 of 100

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$26K	$160K	$22K	9K

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 321

Key Insights for Alaska

Highest-paying payer: Cigna (mean $68K); Lowest-paying payer(s): Anthem and Blue Cross Blue Shield (mean $40K).
Alaska’s payer means span a wide range ($40K to $68K), with Cigna substantially above the other local payers and notably higher than national mean benchmarks for several payers.

Clinical Trials

Acute procedural optimization studies assessing percutaneous coronary interventions (PCI) with multiple stents or intraluminal devices in high-risk anatomies: randomized or pragmatic trials focus on intra-procedural strategies (e.g., imaging-guided deployment, adjunctive atherectomy, staged vs. single-session multivessel PCI) among patients presenting with complex coronary disease requiring treatment of four or more arteries or multiple devices. These studies enroll inpatients undergoing index percutaneous cardiovascular procedures and evaluate immediate procedural success, complication rates (bleeding, vessel dissection, distal embolization), and length of stay. Findings inform interventional technique standards and resource utilization that directly affect inpatient costs and DRG-level reimbursement considerations for complex PCI cases.
Comparative effectiveness research comparing device types and antithrombotic strategies in patients treated with multiple intraluminal devices: observational cohorts or randomized comparative trials examine outcomes for different stent platforms, bioresorbable scaffolds, or adjunctive device use and concurrent antiplatelet/anticoagulant regimens in medically complex patients with multivessel disease. These studies target typical DRG 321 patients who have higher comorbidity burdens (e.g., diabetes, CKD, prior CABG) to assess revascularization durability, repeat revascularization rates, and inpatient adverse events. Results help clinicians and payers evaluate value (clinical benefit vs. cost and complication risk) of specific device and pharmacologic choices in the inpatient setting where device costs and complication-driven expenditures are concentrated.
Post-discharge outcomes and care-transition studies focused on readmission, rehabilitation, and long-term health resource use after complex percutaneous interventions: cohort studies and pragmatic trials evaluate discharge planning, cardiac rehabilitation referral, medication adherence interventions, and early outpatient follow-up timing for patients who underwent PCI with multiple intraluminal devices. The population includes survivors of complex index procedures whose post-acute care needs and readmission risk are elevated due to extensive revascularization and comorbid conditions; endpoints include 30- and 90-day readmissions, major adverse cardiovascular events, and cumulative post-discharge costs. This area is relevant to providers and payers because reducing readmissions and optimizing post-discharge management can substantially impact total cost of care and quality metrics tied to DRG payments.